Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
2027. aug. 31.· PHASE2 · RECRUITING· CTGOV
Vizsgálat
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
2026. nov. 11.· PHASE1_PHASE2 · SUSPENDED· CTGOV
Publikáció
NRAS Mutations in Different Melanoma Histotypes: Molecular and Clinical Implications.
2026. okt. 26.· Current oncology reports· PUBMED
Publikáció
Discovery and Synthesis of Selective Casein Kinase 1δ Degraders for Suppressing Oncogenic NRAS-Mutant Melanoma.
2026. okt. 22.· Journal of medicinal chemistry· PUBMED
Publikáció
The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma.
2026. okt. 8.· Leukemia research reports· PUBMED
Publikáció
Combined talimogene laherparepvec and binimetinib in NRAS-mutated melanoma induces anti-tumor immunity.
2026. szept. 29.· The Journal of clinical investigation· PUBMED
Publikáció
Comment on 'Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma': can survival associations be inferred from selectively tested populations?
2026. szept. 25.· Clinical and experimental dermatology· PUBMED
Publikáció
Histopathologic, Genomic, and Clinical Characteristics of Primary Cutaneous Melanocytic Tumors With Concomitant NRAS Q61 and IDH1 R132C Mutations.
2026. szept. 8.· Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc· PUBMED
Publikáció
The association of NRAS and BRAF mutations with overall survival and surgical outcomes in stage IV colorectal cancer.
2026. szept. 2.· Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract· PUBMED
Vizsgálat
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
2026. aug. 14.· PHASE3 · RECRUITING· CTGOV
Publikáció
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.
2026. aug. 14.· Cancer research· PUBMED
Publikáció
NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.
2026. aug. 11.· Blood· PUBMED
Publikáció
Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.
2026. júl. 31.· Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie· PUBMED
Publikáció
Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens.
2026. júl. 23.· Frontiers in bioscience (Landmark edition)· PUBMED
Publikáció
Structural basis for oligoclonal T cell recognition of a shared NRAS cancer neoantigen.
2026. júl. 20.· Structure (London, England : 1993)· PUBMED
Publikáció
Sirolimus outperforms alpelisib in models of NRAS Q61R -driven vascular overgrowth.
2026. júl. 13.· Blood vessels, thrombosis & hemostasis· PUBMED
Publikáció
Retraction notice to "Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleases" [Cancer Genetics 294-295 (2025) 47-56].
2026. júl. 11.· Cancer genetics· PUBMED
Publikáció
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.
2026. jún. 23.· European journal of cancer (Oxford, England : 1990)· PUBMED
Publikáció
The Molecular Heterogeneity of NRAS Variants in Thyroid Nodules.
2026. jún. 17.· Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery· PUBMED
Publikáció
KRAS/NRAS/BRAF Mutations and Mismatch Repair Deficiency in Patients with Early-Onset Colorectal Cancer: A Clinicopathological Analysis.
2026. jún. 12.· International journal of surgical pathology· PUBMED
Publikáció
Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.
2026. jún. 7.· Cureus· PUBMED
Publikáció
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.
2026. jún. 2.· Leukemia· PUBMED
Publikáció
Melanoma with Blue Nevus-like Morphology Harboring NRAS and NF1 Mutation.
2026. máj. 17.· Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG· PUBMED
Publikáció
High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study.
2026. máj. 15.· Protein expression and purification· PUBMED
Publikáció
Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.
2026. máj. 10.· Carbohydrate polymers· PUBMED
Publikáció
Recurrent primary hyperparathyroidism with ipsilateral multifocal papillary thyroid carcinoma of classical, warthin-like, and follicular variants harboring distinct BRAF and NRAS mutations: a rare case report.
2026. máj. 9.· World journal of surgical oncology· PUBMED
Vizsgálat
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
2026. máj. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.
2026. máj. 1.· Pigment cell & melanoma research· PUBMED
Publikáció
Frequency and Prognostic Value of KRAS, NRAS, and BRAF Mutations in Metastatic Colorectal Cancer: An Iranian Cohort Study.
2026. ápr. 30.· Middle East journal of digestive diseases· PUBMED
Publikáció
Patterns of KRAS, NRAS, and BRAF mutations in colorectal cancer in Chile: a 3-year real-world evidence [2019-2021]-a brief report.
2026. ápr. 30.· Journal of gastrointestinal oncology· PUBMED